ASCO spawns wave of new cancer data

Here's a summary of some of the voluminous cancer data coming from Atlanta's ASCO session. You'll find more in the Clinical Trials Update chart at the bottom of the report.

- here's the summary from MarketWatch

ALSO: Biogen Idec and Schering have released new data that demonstrates patients receiving Zevalin radioimmunotherapy experienced an improved response and remission rates. "We are pleased that the data at this year's ASCO meeting continues to explore Zevalin's ability to impact a broad range of patients, and underscores the growing role that Zevalin can play in the standard of care for lymphoma," said Dr. Wayne Saville, director of Medical Affairs for Biogen Idec. Report

PLUS: Spectrum Pharmaceuticals announced that lead drug candidate Satraplatin appeared to be well tolerated in a clinical trial. Report